Cell Therapeutics' Pixantrone Advisory Committee May Include Updated Results Of Pivotal Trial

FDA declined to give the NME for recurring, aggressive non-Hodgkin's lymphoma priority review, but the firm hopes that progression free survival data and safety argument will be compelling to ODAC.